Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2791186 | 1.00 | NFE2L2 (0.59) | NFE2L2MEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL11710569 | 0.88 | SMN1; SMN2 (0.57) | NFE2L2MEN1KMT2AALDH1A1AKR1C3 | |
| SCHEMBL5566136 | 0.84 | AKR1C3 (0.54) | NFE2L2MEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL14990811 | 0.83 | ALDH1A1 (0.57) | MEN1KMT2AALDH1A1TDP1MAPT | |
| SCHEMBL703413 | 0.83 | ALDH1A1 (0.57) | MEN1KMT2AALDH1A1TDP1MAPT | |
| SCHEMBL3794069 | 0.83 | NFE2L2 (0.55) | NFE2L2MEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL3794074 | 0.83 | NFE2L2 (0.55) | NFE2L2MEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL12038091 | 0.83 | NFE2L2 (0.59) | NFE2L2MEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL10984963 | 0.82 | NFE2L2 (0.64) | NFE2L2MEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL566675 | 0.82 | NFE2L2 (0.64) | NFE2L2MEN1KMT2AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| CN-1139571-C | Process for preparing homophenylalanin derivs | ��Ԩ��ѧ��ҵ��ʽ���� | 2004-02-25 | — | — | CN | disclosed |
| CN-1321636-A | Process for preparing homophenylalanin derivs | KANEGAFUCHI CHEMICAL IND (JP) | 2001-11-14 | — | — | CN | disclosed |
| US-6126855-A | Reaction products of lyotropic liquid crystal salt complexes | ELLIOTT STANLEY B (US) | 2000-10-03 | — | — | US | disclosed |
| CN-1217710-A | Gamma-oxo-homophenylalanine derivative and process for producing homophenylalanine derivative by reducing the same | KANEKA CHEMICAL IND CO LTD (JP) | 1999-05-26 | — | — | CN | disclosed |
| US-5833877-A | DIAGMAGNETIC COMPLEX; SUPERCONDUCTORS | ELLIOTT STANLEY B (US) | 1998-11-10 | — | — | US | disclosed |
| WO-1998001511-A1 | REACTION PROCUCTS OF LYOTROPIC LIQUID CRYSTAL SALT COMPLEXES | ELLIOTT STANLEY B (US) | 1998-01-15 | — | — | WO | disclosed |
| US-5595683-A | COMPLEX OF METAL SALT OF BENZOYLPROPIONIC ACID, LATTICE MODIFIER, CYCLIZATION, HUMIDITY SENSORS | ELLIOTT STANLEY B (US) | 1997-01-21 | — | — | US | disclosed |
| US-5443753-A | Reaction products of lyotropic liquid crystal salt complexes | ELLIOTT STANLEY B (US) | 1995-08-22 | — | — | US | disclosed |
| US-5354499-A | Reaction products of lyotropic liquid crystal salt complexes | ELLIOTT STANLEY B (US) | 1994-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | NFE2L2 4825/4885MEN1 4777/4885KMT2A 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.